Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
How long do you continue maintenance immunosuppression in a patient with PR3 ANCA glomerulonephritis with pulmonary involvement?
Related Questions
How do you choose between eculizumab and ravulizumab for patients with acute kidney injury from complement mediated thrombotic microangiopathy?
What instances will you start outpatient steroids in patients with nephrotic syndrome of unknown etiology prior to obtaining a kidney biopsy?
When would you administer the next maintenance dose of rituximab in a patient with ANCA glomerulonephritis who last received an infusion six months ago and has low immunoglobulin levels and an undetectable CD-19 cell count?
What is your treatment approach when managing patients with relapsing lupus nephritis who previously achieved remission with mycophenolate and steroids?
What drives you to choose voclospsorin over tacrolimus given the substantially higher cost?
Do you take any special treatment considerations for elderly patients diagnosed with collapsing FSGS?
Would you recommend genetic testing to determine if there is a potential underlying primary process in a patient with congenital solitary kidney who is presumed to have secondary FSGS?
Are there instances when you would recommend obtaining a 24 hour urine protein measurement in place of spot urine protein studies in patients with acute kidney injury and proteinuria?
What is your preferred initial therapy for patients with IgA nephropathy and more than 1 gram of proteinuria, given the recent approvals of sparsentan and budesonide alongside existing options like prednisone and ACEi/ARBs?
What is your approach to immunosuppressive treatment for patients with crescentic IgA vasculitis and kidney manifestations?
